Agenus Inc (AGEN)vsAstraZeneca PLC (AZN)
AGEN
Agenus Inc
$6.94
+0.73%
HEALTHCARE · Cap: $310.19M
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 46147% more annual revenue ($61.37B vs $132.69M). AGEN leads profitability with a 69.3% profit margin vs 17.0%. AZN appears more attractively valued with a PEG of 1.28. AZN earns a higher WallStSmart Score of 60/100 (C+).
AGEN
Buy58
out of 100
Grade: C
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AGEN.
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Keeps 69 of every $100 in revenue as profit
Strong operational efficiency at 32.7%
Revenue surging 34.4% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -1279.0% — below average capital efficiency
Negative free cash flow — burning cash
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AGEN
The strongest argument for AGEN centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 69.3% and operating margin at 32.7%. Revenue growth of 34.4% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bear Case : AGEN
The primary concerns for AGEN are EPS Growth, Market Cap, Return on Equity.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AGEN profiles as a growth stock while AZN is a mature play — different risk/reward profiles.
AGEN carries more volatility with a beta of 1.40 — expect wider price swings.
AGEN is growing revenue faster at 34.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 58/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agenus Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?